Discover
Recentin (cediranib) / AstraZeneca; Lynparza (olaparib) / Merck (MSD), AstraZenecaLynparza + cediranib: Acceptance of regulatory submission in US for recurrent platinum-resistant ovarian cancer (based on CONCERTO trial) in H2 2020 (AstraZeneca) - Mar 22, 2020 - Annual Report 2019 [Screenshot]
Lynparza (olaparib) / Merck (MSD), AstraZenecaLynparza: Acceptance of regulatory submission in US for BRCA mutated ovarian cancer (based on SOLO-3 trial) in H2 2020 (AstraZeneca) - Mar 22, 2020 - Annual Report 2019 [Screenshot]
Zejula (niraparib) / GSK, ZAI Lab, J&J, TakedaZai Lab announces acceptance of sNDA submission of Zejula (niraparib) for first-line maintenance treatment of ovarian cancer in China by the NMPA (GlobeNewswire) - Mar 16, 2020 - “Zai Lab Limited…announced the China National Medical Products Administration (NMPA) has accepted its supplemental New Drug Application (sNDA) for ZEJULA® (niraparib) as a maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy….GSK submitted a sNDA to the U.S. FDA for the use of ZEJULA in ovarian cancer as first-line maintenance treatment based on the PRIMA study…”
ofranergene obadenovec (VB-111) / VBL TherapeuticsVBL Therapeutics announces year ended december 31, 2019 financial results and provides corporate update (GlobeNewswire) - Mar 19, 2020 - "'The ongoing Phase 3 OVAL trial in platinum resistant ovarian cancer continues to enroll patients as planned and we expect the readout from an important interim analysis by the end of the first quarter....We now look forward to 2020 as a potential turn around year for the company, with three parallel clinical trials for VB-111 and upcoming results from our MOSPD2 programs for inflammation and oncology.'"
Lynparza (olaparib) / Merck (MSD), AstraZenecaLynparza: Expiry of patents in US in 2028, between 2022- 2024 and 2024- 2031 (AstraZeneca) - Mar 21, 2020 - Annual Report 2019: Expiry of patents in China between 2021- 2024 and 2024- 2029; Expiry of patents in EU between 2021- 2029 and between 2024- 2029; Expiry of patents in Japan between 2021- 2029 and 2024- 2033 [Screenshot]
Zejula (niraparib) / GSK, ZAI Lab, J&J, TakedaZejula: Expiry of patents in US in 2030 and EU in 2028 (GSK) - Mar 21, 2020 - Annual Report 2019 [Screenshot]
veliparib (ABT-888) / AbbVieVeliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Subjects With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov) - Mar 16, 2020 - P3; N=1140; Active, not recruiting; Sponsor: AbbVie; Trial primary completion date: Jul 2020 --> May 2019
